Alpha Cognition Inc. Files New Patent for ALPHA-1062, Extending Protection for Alzheimer's Treatment

Alpha Cognition Inc., a biopharmaceutical innovator focused on addressing neurodegenerative disorders, proudly announces the submission of a new composition-of-matter patent safeguarding its flagship candidate, ALPHA-1062, currently under FDA review for mild-to-moderate Alzheimer’s Disease. This application, filed with the USPTO, underscores the global potential of ALPHA-1062's oral formulation. Grounded in pioneering clinical trial insights, this filing underscores ALPHA-1062's distinctiveness. Pending approval, this patent would extend protection for ALPHA-1062 until 2044, complementing existing protections through 2042.